ArticleRenal failure2025
Global burden and health inequalities of acute glomerulonephritis from 1990 to 2021: a systematic analysis of Global Burden Disease Study 2021.
Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Artificial intelligence-powered renal pathology for glomerular disease classification: a systematic review and meta-analysis.Renal failure · 2026Pooled it
- IgA Nephropathy: Epidemiology, Outcomes, and Insights for Primary Glomerulonephritides.Journal of clinical medicine · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAcute glomerulonephritis (GN) is an acute episode of glomerular injury that affects both children and older adults. However, up-to-date data on its incidence, prevalence, mortality, and disability-adjusted life years (DALYs) remain limited. This study aims to provide the latest global trends and underlying health inequalities associated with acute GN.
methodsIncidence, prevalence, mortality, and DALYs per 100,000 population were reported at global, regional, and national levels, along with the Estimated Annual Percentage Change (EAPC). Global trends were analyzed by age, sex, and sociodemographic index (SDI), with forward projections estimated for the year 2040.
resultsGlobally, there were 528,368 (95% Uncertainty Interval [UI], 446,739 to 613,211) incident cases, 35,452 (95% UI, 30,151 to 41,655) prevalent cases, 10,761 (95% UI, 7,668 to 13,463) deaths, and 312,303 (95% UI, 208,981 to 393,514) DALYs attributed to acute GN in 2021. Children aged <14 years and older adults aged >85 years experienced the most severe burden. Frontier analysis revealed that middle SDI countries had the greatest potential to reduce the disease burden. Although the disease burden of acute GN has declined over the past three decades, our projections indicate that its incidence and prevalence will increase by 2040 due to population growth and aging.
conclusionThe global disease burden of acute GN has decreased; however, population growth and aging may be associated with rising incidence and prevalence by 2040. Middle SDI regions bear a disproportionate burden of acute GN, particularly among children and older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.